PUL-042
Prevention of respiratory infections (viral, bacterial, fungal) in immunocompromised patients
Key Facts
About Pulmotect
Pulmotect is advancing PUL-042, an inhaled innate immune stimulant with a unique mechanism of action offering immediate, broad-spectrum protection against respiratory pathogens. The asset has completed Phase 1/2a trials demonstrating safety and proof-of-concept antiviral activity, with Phase 2 studies planned for immunocompromised cancer patients and other at-risk groups. The company is privately held, led by an experienced management and board with deep expertise in drug development, and is positioned to address a significant market opportunity in preventative respiratory care.
View full company profileAbout Pulmotect
Pulmotect is advancing PUL-042, an inhaled innate immune stimulant with a unique mechanism of action offering immediate, broad-spectrum protection against respiratory pathogens. The asset has completed Phase 1/2a trials demonstrating safety and proof-of-concept antiviral activity, with Phase 2 studies planned for immunocompromised cancer patients and other at-risk groups. The company is privately held, led by an experienced management and board with deep expertise in drug development, and is positioned to address a significant market opportunity in preventative respiratory care.
View full company profile